{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 56,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/6",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.45,
        "y": 0.75
      },
      "kind": "callout",
      "text": "IBD represents a multi-billion dollar market opportunity for best-in-class biologics.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8bd1eea-6354-437b-8eb8-20860aff3ecc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "chart",
      "text": "2021 Global IBD Market",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "593897d2-f1cd-4e8a-9333-71a842694577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.25,
        "y": 0.65
      },
      "kind": "metric",
      "text": "$29B+ estimated IBD market globally in 2028.",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "966b5e2d-ed05-4ae4-ad17-ee7013bfdf7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "metric",
      "text": "~1.7M IBD patients diagnosed in the US.",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2bd0dc5-9f78-4a88-bd42-68ec31d3406a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Biologics are the preferred modality for moderate-to-severe patients due to superior benefit-risk profile.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0182842a-1cdb-4c6d-a207-e83a16b87cb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.25,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "IBD makes up 22% of the global $100B+ I&I market.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97db5217-7d3e-45f7-9659-65290a2ba576",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: Global Data, Evaluate Pharma, UpToDate, SVB Leerink.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcb4cd40-3271-4fd1-93de-a2e653116bb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Inflammatory bowel disease is a growing $21B market in which biologics are the preferred modality",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a8a0902-9d32-48dd-8f84-df7c37c88034",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "16b677f5-5b32-44a4-8621-c253d5f027d3",
      "evidence": "paragraph/paragraph: IBD makes up 22% of the global $100B+ I&I market.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}